Literature DB >> 26084350

A comparison study of cognitive deficits in radiologically and clinically isolated syndromes.

Andrés Labiano-Fontcuberta1, M Luisa Martínez-Ginés2, Yolanda Aladro3, Lucía Ayuso4, Alex J Mitchell5, Verónica Puertas-Martín1, Marta Cerezo3, Yolanda Higueras2, Julián Benito-León6.   

Abstract

UNLABELLED: Up until now, no information has existed regarding a comparison of the pattern and frequency of cognitive deficits between radiologically isolated syndrome (RIS) and clinically isolated syndrome (CIS) patients. Within this objective, Rao's Brief Repeatable Battery and Stroop test were administered to 28 RIS patients, 25 CIS patients, and 22 healthy controls.
CONCLUSIONS: The prevalence of cognitive deficits in RIS was similar to that of CIS. Cognitive deficits seem to be present in RIS patients regardless of the presence of risk factors for a future symptomatic demyelinating event.
© The Author(s), 2015.

Entities:  

Keywords:  Clinically isolated syndrome; cognitive impairment; demyelinating disease; depression; information processing speed; radiologically isolated syndrome

Mesh：

Year:  2015        PMID： 26084350     DOI： 10.1177/1352458515591072

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  8 in total

1.  Does the radiologically isolated syndrome exist? A dual-task cost pilot study.

Authors:  Vincenzo Dattola; Anna Lisa Logiudice; Lilla Bonanno; Fausto Famà; Demetrio Milardi; Gaetana Chillemi; Giangaetano D'Aleo; Silvia Marino; Rocco Salvatore Calabrò; Margherita Russo
Journal:  Neurol Sci       Date:  2017-08-22       Impact factor: 3.307

Review 2.  Radiologically isolated syndrome: from biological bases to practical management.

Authors:  Andres G Barboza; Edgar Carnero Contentti; Maria Celeste Curbelo; Mario Javier Halfon; Juan Ignacio Rojas; Berenice A Silva; Vladimiro Sinay; Santiago Tizio; Maria Celica Ysrraelit; Ricardo Alonso
Journal:  Neurol Sci       Date:  2021-01-25       Impact factor: 3.307

3.  Behavioral Changes in Patients with Multiple Sclerosis.

Authors:  Mirjam R Heldner; Sigal Kaufmann-Ezra; Klemens Gutbrod; Corrado Bernasconi; Sandra Bigi; Verena Blatter; Heinrich P Mattle; René M Müri; Rajeev K Verma; Christian P Kamm
Journal:  Front Neurol       Date:  2017-08-28       Impact factor: 4.003

4.  Normal-appearing brain tissue analysis in radiologically isolated syndrome using 3 T MRI.

Authors:  Andrés Labiano-Fontcuberta; Virginia Mato-Abad; Juan Álvarez-Linera; Juan Antonio Hernández-Tamames; María Luisa Martínez-Ginés; Yolanda Aladro; Lucía Ayuso; Ángela Domingo-Santos; Julián Benito-León
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

5.  Using advanced analysis of multifocal visual-evoked potentials to evaluate the risk of clinical progression in patients with radiologically isolated syndrome.

Authors:  J M Miguel; M Roldán; C Pérez-Rico; M Ortiz; L Boquete; R Blanco
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

6.  Gray Matter Involvement in Radiologically Isolated Syndrome.

Authors:  Andrés Labiano-Fontcuberta; Virginia Mato-Abad; Juan Álvarez-Linera; Juan Antonio Hernández-Tamames; M Luisa Martínez-Ginés; Yolanda Aladro; Lucía Ayuso; Ángela Domingo-Santos; Julián Benito-León
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 7.  Recommendations for cognitive screening and management in multiple sclerosis care.

Authors:  Rosalind Kalb; Meghan Beier; Ralph Hb Benedict; Leigh Charvet; Kathleen Costello; Anthony Feinstein; Jeffrey Gingold; Yael Goverover; June Halper; Colleen Harris; Lori Kostich; Lauren Krupp; Ellen Lathi; Nicholas LaRocca; Ben Thrower; John DeLuca
Journal:  Mult Scler       Date:  2018-10-10       Impact factor: 6.312

Review 8.  Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in.

Authors:  Jeroen Van Schependom; Kaat Guldolf; Marie Béatrice D'hooghe; Guy Nagels; Miguel D'haeseleer
Journal:  Transl Neurodegener       Date:  2019-12-09       Impact factor: 8.014
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.